Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT
Gary A. Ulaner,Jorge A. Carrasquillo,Christopher C. Riedl,Randy Yeh,Vaios Hatzoglou,Dara S. Ross,Komal Jhaveri,Sarat Chandarlapaty,David M. Hyman,Brian M. Zeglis,Serge K. Lyashchenko,Jason S. Lewis +11 more
TLDR
Human epidermal growth factor receptor 2 (HER2)-targeted imaging with zirconium 89-pertuzumab PET/CT was successful in detecting HER2-positive metastases in women with Her2-negative primary breast cancer, demonstrating the ability of targeted imaging to identify patients for targeted therapies that might not otherwise be considered.Abstract:
Human epidermal growth factor receptor 2 (HER2)-targeted zirconium 89–pertuzumab PET/CT successfully helped to identify HER2-positive metastases in women with HER2-negative primary breast cancer.read more
Citations
More filters
Journal ArticleDOI
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
George Crișan,Nastasia Sanda Moldovean-Cioroianu,Diana-Gabriela Timaru,Gabriel Andrieș,Calin Cainap,Vasile Chiş +5 more
TL;DR: This systematic review article aims to clarify and disseminate the available scientific literature focused on PET/SPECT radiotracers and to provide an overview of the conducted research within the past decade, with an additional focus on the novel radiopharmaceuticals developed for medical imaging.
Journal ArticleDOI
The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals
Guus A.M.S. van Dongen,Wissam Beaino,Albert D. Windhorst,G.J.C. Zwezerijnen,Daniela E. Oprea-Lager,N. Harry Hendrikse,Cornelis van Kuijk,Ronald Boellaard,Marc C. Huisman,Danielle J. Vugts +9 more
TL;DR: Although 89Zr-immuno-PET is a young tool in drug development, its application is rapidly expanding, with first clinical experiences giving insight why certain drug-target combinations might have better perspectives than others.
Journal ArticleDOI
Radiolabeled Antibodies for Cancer Imaging and Therapy
TL;DR: An overview of the radiolabeled intact antibodies currently in clinical use and those in development is provided, including radioimmunoconjugates, which allows for reduced toxicity compared to conventional radiation therapy and enhances the efficacy of mAbs.
Journal ArticleDOI
PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.
TL;DR: In this article, the authors summarized the recent preclinical and clinical data on agents for Positron Emission Tomography (PET) and single photon emission tomography (SPECT) imaging of EGFR-family receptors in oncology.
Journal ArticleDOI
89Zr-PET imaging in humans: a systematic review
Maria Silvia De Feo,Mariano Pontico,Viviana Frantellizzi,Ferdinando Corica,Flaminia De Cristofaro,Giuseppe De Vincentis +5 more
TL;DR: A systematic literature search of articles suiting the inclusion criteria was conducted on Pubmed, Scopus, Central, and Web Of Science databases, including papers published from January 1967 to November 2020 as mentioned in this paper.
References
More filters
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
TL;DR: Qualitative and quantitative approaches to 18F-FDG PET response assessment have been applied and require a consistent PET methodology to allow quantitative assessments and the proposed PERCIST 1.0 criteria should serve as a starting point for use in clinical trials and in structured quantitative clinical reporting.
Journal ArticleDOI
Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
TL;DR: The processes shaping the cancer genome are explored, placing these within the context of tumor evolution and their impact on intratumor heterogeneity and drug development.
Journal ArticleDOI
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
Eli C. F. Dijkers,T.H. Oude Munnink,Jos G. W. Kosterink,Adrienne H. Brouwers,Piet L. Jager,J R de Jong,G.A.M.S. (Guus) van Dongen,Carolien P. Schröder,M. N. Lub-de Hooge,E.G.E. de Vries +9 more
TL;DR: PET scanning after administration of the monoclonal antibody zirconium‐89 at appropriate doses allows visualization and quantification of uptake in HER2‐positive lesions in patients with metastatic breast cancer.
Journal ArticleDOI
HER2-targeted therapies — a role beyond breast cancer
Do Youn Oh,Yung-Jue Bang +1 more
TL;DR: The current role of HER2-targeted therapies beyond breast cancer is described and the potential of novel Her2- targeted agents that are currently in clinical development are highlighted, including antibody–drug conjugates and bispecific antibodies targeting HER2.